Me and my BOT: contentious, enigmatic and controversial

As the months pass, I’m finding myself becoming more and more attached to my BOT diagnosis.  When a bunch of hardcore scientists refer to a BOT as contentious, enigmatic and controversial, I can’t help but smile. It seems surprisingly fitting.  As another research paper presents its analysis of its selected data to predict BOT prognosis (this time we’re back on micropapillary patterns being associated with poorer prognosis), it’s reassuring to know that 

“[f]ew tumours have invited contention and controversy so disproportionately to their incidence as borderline ovarian tumours (BOTs), deriving from their enigmatic behaviour, uncertain pathogenesis, and controversial management.”

Keep smiling.

Vasconcelos I, Darb-Esfahani S, Sehouli J. Serous and mucinous borderline ovarian tumours: differences in clinical presentation,high-risk histopathological features, and lethal recurrence rates. BJOG 2016;123:498–508